A Phase 2 interventional study of masitinib and masitinib in Rheumatoid Arthritis, sponsored by AB Science. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-13.
Sponsored by AB Science · Phase 2, Interventional, and Treatment
A 12-week with possible extension, phase II study to compare efficacy and safety of masitinib at 3 and 6 mg/kg/day in combination with methotrexate, in treatment of patients with active rheumatoid arthritis refractory to standard treatments.
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's enrollment of 20 is below the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →AB Science is the lead sponsor of 39 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
masitinib 3 mg/kg/day
Drug: masitinib
masitinib 6 mg/kg/day
Drug: masitinib
3 mg/kg/day oral route
Also known as: AB1010
masitinib 6 mg/kg/day oral route
Also known as: AB1010
American College of Rheumatology Score 50
Time frame: week 12
DAS28
Time frame: week 4, 8 and 12
No study locations are listed for this record.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AB Science